Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab and Daratumumab in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis
NCT07638683Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab in multiple myeloma (MM), light-chain amyloidosis, sponsored by Zhongshan Hospital, Fudan University. Started May 2026; status: recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on NCT07638683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07638683.